Brief: Jacobio Pharmaceuticals Gets Investigational New Drug Approval For Jab-2485 In U.S.
17/01/2022 01:52
Jan 17 (Reuters) - JACOBIO PHARMACEUTICALS 1167.HK :
* INVESTIGATIONAL NEW DRUG (IND) APPROVAL FOR- AURORA A
INHIBITOR
JAB-2485 IN UNITED STATES
Further company coverage: 167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan